Reduced nocturnal hypoglycaemia with basal insulin peglispro compared with insulin glargine: pooled analyses of five randomized controlled trials

Diabetes, Obesity and Metabolism

Volumn 18, Issue 11, 2016, Pages 1093-1097

  Rosenstock, Julio ^a   Marre, Michel ^b   Qu, Yongming ^c   Zhang, Shuyu ^c   Bastyr, Edward J ^c,d   Prince, Melvin J ^c   Chang, Annette M ^c  

^a DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^b BICHAT HOSPITAL   (France)

^c ELI LILLY AND COMPANY   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

basal insulin peglispro; hypoglycaemia; insulin glargine; nocturnal hypoglycaemia

Indexed keywords

HEMOGLOBIN A1C; INSULIN GLARGINE; INSULIN PEGLISPRO; BASAL INSULIN PEGLISPRO; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; INSULIN LISPRO; MACROGOL DERIVATIVE;

ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAINTENANCE THERAPY; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); ADULT; AGED; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; FEMALE; GLUCOSE BLOOD LEVEL; MALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY;

ADULT; AGED; BLOOD GLUCOSE; CIRCADIAN RHYTHM; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; INSULIN GLARGINE; INSULIN LISPRO; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES;

EID: 84990189269     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12757     Document Type: Article

References (19)

1. International Hypoglycaemia Study Group. Minimizing hypoglycemia in diabetes. Diabetes Care. 2015;38:1583–1591.
2. King P, Kong MF, Parkin H, Macdonald IA, Tattersall RB. Well-being, cerebral function, and physical fatigue after nocturnal hypoglycemia in IDDM. Diabetes Care. 1998;21:341–345.
3. Sinha VP, Howey DC, Choi SL, Mace KF, Heise T. Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2014;16:344–350.
4. Henry RR, Mudaliar S, Ciaraldu TP, et al. Basal insulin peglispro demonstrates preferential hepatic versus peripheral action relative to insulin glargine in healthy subjects. Diabetes Care. 2014;37:2609–2615.
5. Bergenstal RM, Lunt H, Franek E, et al. A randomized, double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 3. Diabetes Obes Metab. 2016, DOI: 10.1111/dom.12698. [Epub ahead of print].
6. Blevins T, Pieber TR, Colon VG, Zhang S, Bastyr EJ III, Chang AM. Randomized double-blind clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 2 diabetes: IMAGINE 4. Diabetes Obes Metab. 2016, DOI: 10.1111/dom.12696. [Epub ahead of print].
7. Buse JB, Rodbard HW, Trescoli SC, et al. Randomized clinical trial comparing basal insulin peglispro and insulin glargine in patients with type 2 diabetes previously treated with basal insulin: IMAGINE 5. Diabetes Care. 2016;39:92–100.
8. Davies MJ, Russell-Jones D, Selam JL, et al. Basal insulin peglispro vs insulin glargine in insulin-naive type 2 diabetes: IMAGINE 2 randomized trial. Diabetes Obes Metab. 2016, DOI: 10.1111/dom.12712. [Epub ahead of print].
9. Garg S, Dreyer M, Jinnouchi H, et al. A randomized clinical trial comparing basal insulin peglispro and insulin glargine, in combination with prandial insulin lispro, in patients with type 1 diabetes: IMAGINE 1. Diabetes Obes Metab. 2016, DOI: 10.1111/dom.12738. [Epub ahead of print].
10. Bastyr EJ III, Zhang S, Mou J, Hackett AP, Raymond SA, Chang AM. Performance of an electronic diary system for intensive insulin management in global diabetes clinical trials. Diabetes Technol Ther. 2015;17:571–579.
11. Qu Y, Luo J. Estimation of group means when adjusting for covariates in generalized linear models. Pharm Stat. 2015;14:56–62.
12. Bergenstal RM, Rosenstock J, Arakaki RF, et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care. 2012;35:2140–2147.
13. Rosenstock J, Bergenstal RM, Blevins TC, et al. Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study. Diabetes Care. 2013;36:522–528.
14. Garg S, Selam JL, Bhargava A, et al. Similar HbA1c reduction and hypoglycaemia with variable- vs fixed-time dosing of basal insulin peglispro (BIL) in type 1 diabetes: IMAGINE 7 Study. Diabetes Obes Metab. 2016, DOI: 10.1111/dom.12740. [Epub ahead of print].
15. Ratner RE, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15:175–184.
16. Ritzel R, Roussel R, Bolli GB, et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab. 2015;17:859–867.
17. Gregory JM, Kraft G, Scott MF, et al. Insulin delivery into the peripheral circulation: a key contributor to hypoglycemia in type 1 diabetes. Diabetes. 2015;64:3439–3451.
18. Kilpatrick ES, Rigby AS, Goode K, Atkin SL. Relating mean blood glucose and glucose variability to the risk of multiple episodes of hypoglycaemia in type 1 diabetes. Diabetologia. 2007;50:2553–2561.
19. Qu Y, Jacober SJ, Zhang Q, Wolka LL, DeVries JH. Rate of hypoglycemia in insulin-treated patients with type 2 diabetes can be predicted from glycemic variability data. Diabetes Technol Ther. 2012;14:1008–1012.